AzTrials
AzTrials

Pelvic Organ ProlapsePACTNCT02277925

Permanent Versus Absorbable Colpopexy Trial

A study testing Polytetrafluoroethylene and Polydioxanone in people with Pelvic Organ Prolapse, run by University of North Carolina, Chapel Hill at 5 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Primary Aim: The primary aim of this randomized controlled trial (RCT) is to compare vaginal mesh and suture exposure rates in women undergoing robotic total hysterectomy and sacrocolpopexy with a light-weight polypropylene mesh (Upsylon™ y-mesh) using permanent (polytetrafluoroethylene, Gore-Tex) versus delayed… Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Pelvic Organ Prolapse
What is being tested?
Polytetrafluoroethylene and Polydioxanone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
204 participants
Where
5 sitesUnited States
Study dates
7 Apr 2015to 7 Oct 2019
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18
  • Subject must have apical with anterior or posterior vaginal prolapse with leading edge of prolapse to or beyond the hymen. This is defined as stage 2-4 pelvic organ prolapse ( C > - (TVL / 2) AND Ba or Bp ≥ 0 by the POP)
  • Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3, response of 2 or higher (i.e., responses of "somewhat", "moderately", or "quite a bit")
  • Eligible for robotic or laparoscopic sacral colpopexy
  • Desires surgical treatment for primary, symptomatic uterovaginal prolapse
  • English speaking
  • Willing to undergo hysterectomy

Who cannot join

  • Patients who had prior hysterectomy
  • Patients who are not surgical candidates due to medical comorbidities
  • Current foreign body complications (including but not limited to erosion, fistula, abscess). This covers foreign bodies of any type (e.g. synthetic and biologic including allograft, xenograft).
  • Desires uterine conservation
  • Inability to give informed consent or to complete the testing or data collection
  • Anticipated circumstances resulting in an inability to follow up (geographic relocation, etc).
Show all 17Show fewer
  • Pregnant or intends to become pregnant
  • Active/chronic systemic infection including any gynecologic infection, untreated UTI or tissue necrosis
  • History of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical)
  • Prior or currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area
  • Subject has taken systemic steroids (within the last month), or immunosuppressive or immunomodulatory treatment (within the last 3 months)
  • Systemic connective tissue disease (e.g. scleroderma, Marfan's syndrome, Ehlers Danhlos, collagenosis, polymyositis or polymyalgia rheumatica)
  • Chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis
  • Poorly controlled diabetes mellitus (DM), as indicated by Hemoglobin A1c > 9
  • Those requiring concomitant rectopexy
  • Subject is not able to conform to steep trendelenburg position
  • Known sensitivity to polypropylene

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

United States5 sites
  • Augusta University Medical Center

    Augusta, Georgia, 30912

  • UNC Chapel Hill

    Chapel Hill, North Carolina, 27516

  • Carolinas HealthCare System

    Charlotte, North Carolina, 28207

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina, 27595

Other trials in United States

About this study

Official title: Permanent Versus Delayed-absorbable Monofilament Suture for Vaginal Graft Attachment During Minimally-invasive Total Hysterectomy and Sacrocolpopexy: A Randomized Clinical Trial

Primary Aim:

The primary aim of this randomized controlled trial (RCT) is to compare vaginal mesh and suture exposure rates in women undergoing robotic total hysterectomy and sacrocolpopexy with a light-weight polypropylene mesh (Upsylon™ y-mesh) using permanent (polytetrafluoroethylene, Gore-Tex) versus delayed absorbable monofilament (2-0 polydioxanone, PDS) sutures through 1-year.

Read more

Secondary Aims:

  1. To compare the 1-year composite success rate (leading edge of prolapse is at or above the hymen and apex has descended less than 1/3 of the vaginal length, no subjective feeling of bulge; and no retreatment for pelvic organ prolapse (POP) or vaginal mesh exposure) of permanent versus delayed absorbable sutures for mesh graft attachment during robotic total hysterectomy and sacrocolpopexy.
  2. To evaluate adverse outcomes in each group
Read the detailed description

Symptomatic pelvic organ prolapse is common and 13%1 to 19%2,3 of women undergo surgical repair. Reconstructive pelvic surgery is broadly divided into procedures that rely on existing native tissue versus the use of graft augmentation, either with synthetic or biologic materials. Native tissue vaginal repair, while associated with the lowest rate of surgical complications,4 has a high rate of recurrent prolapse. A recent randomized trial of uterosacral versus sacrospinous ligament fixation for POP demonstrated a 30% recurrence rate at 2 years.3

Abdominal sacrocolpopexy (SCP) is considered to be the most durable operation for advanced pelvic organ prolapse with reoperation rates of less than 5%.5-7 Minimally-invasive techniques of SCP, such as robotic-assistance, are associated with improved recovery times and less cost than abdominal SCP without a demonstrable difference in efficacy.8,9 While traditionally reserved for women with vaginal vault prolapse, SCP is increasingly considered as a primary surgical option for women who present with uterovaginal prolapse in an attempt to improve longer-term surgical outcomes. The optimal management of the uterus and cervix in these cases is unclear.

Rationale for total versus supracervical hysterectomy with concomitant SCP

While supracervical hysterectomy and concomitant SCP are associated with lower rates of mesh exposure,10-12 potential negative consequences of a supracervical hysterectomy include morcellation of unanticipated uterine malignancy,13 cervical stump prolapse/elongation, cyclic vaginal bleeding, and reduced anterior vaginal support (Myers EM, Matthews et al., in press). When conducting a supracervical hysterectomy, power morcellators are the most common method used to extract the amputated uterine corpus. The potential risks of power morcellation were recently highlighted by the FDA safety notification which focused on the potential to disseminate fragments of an undiagnosed uterine leiomyosarcoma throughout the abdomen, which negatively impacts prognosis (http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm393576.htm). With these recent developments the focus has shifted towards performing total hysterectomy for delivery of an intact specimen through the vagina.

Vaginal mesh exposure has been a problematic complication with both abdominal SCP and minimally invasive SCP. Widely disparate rates of mesh exposure ranging from 0%14 to 27%15 have been reported. A systematic review of ASCP outcomes in 2004 reported an overall rate of 3.4%,6 and a recent meta-analysis of robotic-assisted SCP reported an overall rate of 2%.16 Some consistent risk factors for mesh exposure are non-Type 1 polypropylene mesh (knitted, small-pore mesh materials) and smoking.17,18 Some studies have identified total hysterectomy as a significant risk factor. In an evaluation of patients enrolled in the CARE trial, 6% had evidence of mesh exposure at 2 years, with concomitant hysterectomy presenting almost a 5-fold increased risk.18 The rate at 6 years rose to 10.5%. 5 More than 50% of subjects in this trial, however, had a non-Type 1 polypropylene mesh. Akyol et al. demonstrated a 2-fold increased risk (12%)19 and Bensinger et al. a 7-fold increased risk (8.2%)20 of concomitant total hysterectomy. In contrast, 4 retrospective studies in which Type1 polypropylene mesh was used revealed no increased risk of mesh erosion with concomitant total hysterectomy.14,21-23 These widely discrepant rates of mesh exposure may be related to surgical technique, graft material and/or suture materials used for mesh attachment.

Rationale for need to study suture material for mesh attachment during SCP

The effect of suture on mesh exposure may be as significant as concomitant hysterectomy or mesh type. At UNC, we reported on mesh exposure using a permanent suture for mesh attachment during SCP with and without concomitant total hysterectomy, with rates of 8% at 1 year.24 There is some evidence that a delayed absorbable suture may reduce the risk of mesh or suture erosion. In a retrospective review comparing braided permanent suture to delayed absorbable monofilament suture for SCP mesh attachment, rates of mesh exposure were reduced in the absorbable suture group (3.7% vs 0%), with no associated POP recurrence.25 Similarly, in another retrospective review, when delayed absorbable monofilament suture was used for SCP mesh attachment in 67 women undergoing total abdominal hysterectomy and SCP, no mesh exposures were noted at a median follow up of 27 months.26 The use of permanent sutures for vaginal mesh attachment has historically been advocated as a means to reduce POP recurrence risk; yet, no prospective study has definitively answered this question. The tradeoff of using a permanent suture may be an increased risk of mesh or suture exposure, as a permanent suture that has breached the vaginal epithelium may serve as a nidus for bacterial seeding, theoretically increasing the risk of mesh exposure. As SCP appears to be a more durable procedure for women with advanced uterovaginal prolapse, there is an urgent need to identify the ideal method of vaginal mesh attachment that minimizes the risk of mesh-related complications while maintaining effectiveness of the POP repair.

Choice of mesh material

Upsylon™ (Boston Scientific, Natick, MA) is a pre-formed Y-mesh that is light-weight (25 g/m2), composed of Type I polypropylene material, with a pore size of 2.8 mm2 and surface area ration of 1.11. It was FDA approved in 2012. The mesh is blue in color that may aide in the ability to detect even small areas of mesh exposure and erosion. No data currently exist regarding the performance of this particular mesh product in SCP. It is lighter in mesh weight than the IntePro™ y-mesh (American Medical Systems, Minneapolis, MN), which we previously used in the comparative trial of robotic to abdominal SCP in which our mesh exposure rates were 8%.

The primary aim of this randomized trial, therefore, is to test the hypothesis that use of the Upsylon™ mesh with a delayed absorbable suture for mesh attachment at the time of robotic-assisted total laparoscopic hysterectomy and SCP will reduce the risk of vaginal mesh and/or suture exposure compared to a permanent monofilament suture. Secondary aims will include an evaluation of the effect of this light-weight mesh and absorbable suture on prolapse and quality of life outcomes and surgical complications at 1 year after surgery.

Being tested
Polytetrafluoroethylene, Polydioxanone
Keywords
Pelvic Organ Prolapse, Vaginal mesh exposure rates, Vaginal suture exposure rates
Medical subject headings
Pelvic Organ Prolapse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PolytetrafluoroethyleneOther

    Also called Gore-Tex permanent suture

    Suture used to attach mesh during sacral colpopexy surgery

  • PolydioxanoneOther

    Also called 2-0 PDS delayed absorbable monofilament suture

    Suture used to attach mesh during sacral colpopexy surgery

Study groups in NCT02277925
Study groupRoleWhat they receive
Gore-Tex permanent sutureActive comparatorParticipants in this arm will receive Gore-Tex permanent suture
Receives: Other: Polytetrafluoroethylene
PDS delayed absorbable sutureExperimentalParticipants in this arm will receive 2-0 PDS delayed absorbable suture
Receives: Other: Polydioxanone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Vaginal Mesh or Suture Exposure

    Total number of participants with vaginal mesh and/or suture exposure thru 1 year

    Measured: 1 year

Secondary outcomes (2)
  1. Number of Participants With Treatment Success

    Total number of participants with treatment success, which was a composite measure of 1) leading edge of prolapse not beyond hymen and apex not descended > 1/3 of vaginal length, 2) no subjective feeling of bulge on validated questionnaire, and 3) no prolapse re-treatment with pessary or surgery

    Measured: 1 year

  2. Pelvic Floor Distress Inventory-20 (PFDI-20) Mean Score

    Condition-specific questionnaire, pelvic floor distress inventory-20 (PFDI-20) is used. Minimum value is 0. Maximum is 300. Higher scores mean more bothersome symptoms.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2014 (estimated)
  2. Study start7 Apr 2015
  3. Primary completion7 Oct 2019
  4. Study completion7 Oct 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
204 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02277925
Sponsor's protocol ID
14-2402
Acronym
PACT
Status last verified
Oct 2019
First submitted
27 Oct 2014
Last updated
19 Nov 2019
Data monitoring committee
Yes

Publications

  • Matthews CA, Geller EJ, Henley BR, Kenton K, Myers EM, Dieter AA, Parnell B, Lewicky-Gaupp C, Mueller MG, Wu JM. Permanent Compared With Absorbable Suture for Vaginal Mesh Fixation During Total Hysterectomy and Sacrocolpopexy: A Randomized Controlled Trial. Obstet Gynecol. 2020 Aug;136(2):355-364. doi: 10.1097/AOG.0000000000003884.

    PubMed 32649494

Questions about this trial

What is this clinical trial studying?

A study testing Polytetrafluoroethylene and Polydioxanone in people with Pelvic Organ Prolapse, run by University of North Carolina, Chapel Hill at 5 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Nov 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Vaginal Mesh or Suture Exposure (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02277925, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Nov 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in